Vytorin Articles
Merck & Co to pay $688 million to settle investor law suits; Teva could face $2.1 billion damages
15 February 2013
Merck & Co prevails in patent fight over Zetia and Vytorin; GSK files for EU approval of melanoma products
8 February 2013
US FDA mixed views on Vytorin and Zetia
26 January 2012
FDA panel gives unanimous backing for Merck & Co’s Vytorin for some kidney disease patients
4 November 2011
Lab Rovi soon to market Vytorin and Absorcol in Spain, the first of the five licenses from Merck & Co
19 January 2011
World's largest kidney disease trial shows big benefits from reducing cholesterol with Vytorin; Merck & Co to apply for CKD indication
22 November 2010
Merck & Co sues Impax Labs over Vytorin patent infringement in USA, as firm faces “patent cliff”
24 August 2010
Merck & Co rises 2.3% as it beats 4th quarter 2009 sales forecast, boosted by Schering-Plough
17 February 2010
Merck & Co remains confident in Zetia and Vytorin, despite studying questioning the drugs
16 November 2009
One time gain triples Merck & Co’s 3rd quarter 2009 earnings, beating forecasts; EU clears S-P deal
23 October 2009
Schering-Plough profits beat forecasts
21 April 2009
Study shows no higher cancer risk with Vytorin
27 March 2009
Sweden's TLV rejects 1st-line use of Pfizer's Lipitor, cites "20 times" cost differential
23 February 2009
Stock Commentary - New York week to Feb 9, 2009
16 February 2009
Stock Commentary - New York week to Feb 2, 2009
9 February 2009
New US DTC guidelines from PhRMA dismissed by leading Democrats
22 December 2008
Merck & Co's 2009 outlook below predictions due to forex effects and restructuring costs
15 December 2008
Stock Commentary - New York week to Dec 1, 2008
8 December 2008
S-P claims superior pipeline to competitors; new drugs could make $7B in next 4 years
8 December 2008
Negative press has compromised Vytorin as first-line therapy; DR
17 November 2008
S-P profit falls 21%, still up on predictions
27 October 2008
Divided opinion on Vytorin despite
8 September 2008
FDA investigates Vytorin link to cancer risk in SEAS study
1 September 2008
Merck & Co income still up despite low sales
28 July 2008
Stock Commentary - New York week to July 21, 2008
28 July 2008
UPDATE: FDA panel votes in favor of outcomes over surrogate markers in diabetes drug approval
7 July 2008
New effort to curb DTC ads by US Democrats
12 May 2008
S-P profit down, sales up on Organon buy
5 May 2008
Merck & Co 1Q results saved by AZ payout
28 April 2008
Stock Commentary - New York week to April 7, 2008
14 April 2008
Class action against Merck & Co
14 April 2008
Schering-Plough plans $1.5B cost cuts due to market pressures and cholesterol drug woes
7 April 2008
Zetia "could be expensive placebo," ACC hears
7 April 2008
Late-stage Cordaptive trial stalls on IMT issue
7 April 2008
Stock Commentary - New York week to March 31, 2008
7 April 2008
Crestor sales hopes raised by JUPITER trial
7 April 2008
Stock Commentary - New York week to March 3, 2008
10 March 2008
Doctors claim statins cause memory loss
25 February 2008
US congressional committee widens Vytorin investigation
18 February 2008
S-P's 4th-qtr 2007 results hit by Organon buy
18 February 2008
Stock Commentary - New York week to Feb 4, 2008
11 February 2008
S-P/Merck & Co account for ENHANCE delay
4 February 2008
Vioxx costs see Merck & Co swing to $1.6B loss
4 February 2008
US clinic ships 19,000 drug firm gifts to Cameroon
28 January 2008
Drugmakers accused of delaying ENHANCE data
28 January 2008
Stock Commentary - New York week to Jan 21, 2008
28 January 2008
ENHANCE data now expected March 2008
26 November 2007
Stock Commentary - New York week to Oct 29, 2007
5 November 2007
Stock Commentary - New York week to October 22, 2007
29 October 2007
S-P's 3rd-qtr 2007 net income surges 149%
29 October 2007
Merck & Co's 3rd-qtr 2007 sales jump 12%
29 October 2007
Merck & Co to surpass Pfizer in cholesterol-lowering market
17 September 2007
Merck & Co to surpass Pfizer in cholesterol-lowering market
17 September 2007
S-P's 2nd-quarter 2007 EPS doubles to $0.34
30 July 2007
Stock Commentary - New York - week to July 16, 2007
23 July 2007
Medicines Australia welcomes govt boost
14 May 2007
Merck & Co's 1st-qtr income climbs 12%
30 April 2007
Stock Commentary - New York week to April 16, 2007
23 April 2007
Merck & Co/S-P enter new LDL drug accord
2 April 2007
Merck & Co's 4th-qtr income plunges 58%
5 February 2007
Stock Commentary - New York week to Jan 29, 2007
5 February 2007
Stock Commentary - New York week to December 4
11 December 2006
S-P/Merck & Co's Inegy cuts LDL-C more than Lipitor
27 November 2006
S-P's 3rd-qtr 2006 net income improves
30 October 2006
Stock Commentary - New York week to Sept 18, 2006
25 September 2006
Strong combo data for AstraZeneca's Crestor
26 June 2006
Vytorin reduces LDL-cholesterol by 52%
20 March 2006
Merck & Co beats forecasts; profit up 2%
6 February 2006
Schering-Plough back in profit for 1st-qtr
22 April 2005
Vioxx loss drags on Merck & Co results
22 April 2005
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
